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BRIEF DEFINITIVE REPORT
        NK cells participate in host protection by 
eliminating cells with altered expression of 
self  –  MHC class I (MHC-I), which can result 
from viral infection or transformation (  1  ). Al-
though we are beginning to appreciate a role 
for viral and stress-induced ligands in NK cell 
activation, the best described regulatory mech-
anism of NK cell activity is the expression of 
inhibitory receptors for self  –  MHC-I ligands 
by mature NK cells with high cytotoxic po-
tential. In man, killer Ig-like receptors (KIRs) 
recognizing the classical MHC-I molecules 
HLA-A, -B, or -C are expressed on the pre-
dominate peripheral NK cell (CD56  lo  CD16  +  ) 
subset, which possesses abundant intracellular 
perforin and granzymes and displays sponta-
neous cytotoxicity (  1  ). In contrast, CD-
56  hi  CD16        NK cells rarely express KIRs, and 
because they are more prevalent in blood early 
after bone marrow transplant (  2, 3  ), give rise 
to CD56  lo  CD16  +   NK cells when transferred 
into NOD/SCID mice (  4  ), and have longer 
telomeres than CD56  lo  CD16  +   NK cells (  5  ), it 
is likely that CD56  hi  CD16        NK cells are (or 
contain within this population) precursors of 
CD56  lo  CD16  +   NK cells; however, the tools 
to defi  nitively prove this hypothesis are lacking. 
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  The in vivo requirements for human natural killer (NK) cell development and differentiation 
into cytotoxic effectors expressing inhibitory receptors for self  –  major histocompatability 
complex class I (MHC-I; killer Ig-like receptors [KIRs]) remain undefi  ned. Here, we dissect 
the role of interleukin (IL)-15 in human NK cell development using Rag2      /         c      /      mice 
transplanted with human hematopoietic stem cells. Human NK cell reconstitution was 
intrinsically low in this model because of the poor reactivity to mouse IL-15. Although 
exogenous human IL-15 (hIL-15) alone made little improvement, IL-15 coupled to IL-15 
receptor      (IL-15R    ) signifi  cantly augmented human NK cells. IL-15  –  IL-15R     complexes 
induced extensive NK cell proliferation and differentiation, resulting in accumulation of 
CD16  +  KIR  +   NK cells, which was not uniquely dependent on enhanced survival or preferen-
tial responsiveness of this subset to IL-15. Human NK cell differentiation in vivo required 
hIL-15 and progressed in a linear fashion from CD56  hi  CD16       KIR        to CD56  lo  CD16  +  KIR       , and 
fi  nally to CD56  lo  CD16  +  KIR  +  . These data provide the fi  rst evidence that IL-15 trans-presen-
tation regulates human NK cell homeostasis. Use of hIL-15 receptor agonists generates a 
robust humanized immune system model to study human NK cells in vivo. IL-15 receptor 
agonists may provide therapeutic tools to improve NK cell reconstitution after bone mar-
row transplants, enhance graft versus leukemia effects, and increase the pool of IL-15  –
  responsive cells during immunotherapy strategies. 
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    RESULTS AND DISCUSSION   
  Human hematopoietic chimerism and NK cell development 
in HIS mice 
  Human HSCs engrafted into newborn BALB/c Rag2      /         c      /      
mice develop into mature myeloid and lymphoid cells (  15, 16  ). 
We used this approach to investigate human NK cell devel-
opment in vivo  .   8  –  12 wk after HSC engraftment, HIS mice 
displayed human hematopoietic chimerism in all organs 
analyzed, with human thymopoiesis, B lymphopoiesis, and my-
elopoiesis evident (  Fig. 1, A and B,   and Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20082013/DC1).   
Using an NK cell  –  specifi  c antibody (anti-NKp46), we identi-
fi  ed human NK cells in all lymphoid organs of HIS mice, al-
though at low frequencies, typically between 0.3 and 1.5% of 
human lymphocytes (  Fig. 1 A  ). Both CD56  hi  CD16        and 
CD56  lo  CD16  +   NK cells subsets are present, with the majority 
of NK cells having the latter phenotype (  Fig. 1 C  ). Interest-
ingly, some CD16  +   cells expressed CD56 at levels indistin-
guishable from non  –  NK cells. These CD56  lo   cells are NK 
cells, as they express NKp46, NKG2D, CD94, and, like their 
counterparts in man, KIRs, whereas CD56  hi  CD16        cells are 
rarely KIRs  +   (  Fig. 1 C  ). NKp46  +   cells present a phenotype 
consistent with peripheral NK cells in man including expres-
sion of CD122 (IL-2R    ), NKG2A, CD161, but not CD3 
(  Fig. 1 D  ). In vivo  –  generated human NK cells express high 
levels of intracellular granzyme B and IFN-     when stimu-
lated with IL-12 and -18 ex vivo, and they degranulate when 
co-cultured with K562 human leukemia cells as determined 
by expression of CD107a (  Fig. 1 E  ). 
  IL-15 is a pleiotropic cytokine essential for mouse NK 
cell development (  10  ). Given the sparse number of human 
NK cells, we hypothesized that IL-15 availability in this HIS 
model might be suboptimal. HIS mice represent a hybrid 
human  –  mouse system where cytokine receptor compatibility 
between species may not exist. Specifi  cally, although human 
IL-15 (hIL-15) induces survival and proliferation of mouse 
NK cells (  17, 18  ), it is not clear whether the reverse is true. 
This is a critical question, as we expect most of the IL-15 in 
HIS mice to be mouse-derived given the low human my-
eloid (  15  ) or absent epithelial/stromal cell chimerism (cells 
likely to be sources of IL-15) (  10, 19  ). We found that human 
NK cells cultured in vitro with hIL-15 proliferated exten-
sively (predominately the CD56  hi  CD16        subset); this was in 
contrast to those cultured in mouse IL-15 (mIL-15), which 
itself suffi   ciently induced proliferation of mouse NK cells 
(  Fig. 1 F   and Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20082013/DC1). Given that mIL-15 is 
trans-presented in vivo, we investigated the eff  ect of cultur-
ing human NK cells with low concentrations of IL-15 alone 
or IL-15 trans-presented by IL-15R    -Fc of the same or al-
ternate species. Irrespective of which species of IL-15R     was 
used, mIL-15 failed to induce human NK cell proliferation, 
although some cells survived when mIL-15 was combined 
with hIL-15R    -Fc (  Fig. 1 G  ). In contrast, hIL-15R     was 
clearly superior in inducing NK cell proliferation compared 
with mIL-15R     when combined with hIL-15 (  Fig. 1 G  ). 
  Although inhibitory KIRs control reactivity of mature 
NK cells, their expression also infl  uences the functional mat-
uration of developing NK cells, as NK cells expressing at least 
one KIR-recognizing self  –  MHC-I have a lower threshold of 
activation and appear more functional than NK cells express-
ing no KIRs or those only expressing KIRs recognizing non-
self  –  MHC-I ligands (  6  ). In addition, patients lacking the 
transporter associated with antigen processing have dramati-
cally reduced MHC-I surface expression and, consequently, 
hyporesponsive NK cells to MHC-I  –  defi  cient cells (  7  ). KIR  +   
NK cells are present in these patients, indicating that normal 
MHC-I expression itself is not required for KIR expression 
(  7  ). This phenomenon termed   “  licensing  ”   or   “  disarming  ”   has 
been better characterized in mice, and suggests a role for 
KIR  –  self  –  MHC-I interactions during human NK cell devel-
opment. Given the importance of KIR expression in regulat-
ing NK cell function, knowledge of elements infl  uencing 
KIR acquisition would improve our understanding and clini-
cal approaches to diseases where KIR and HLA haplotypes 
infl  uence susceptibility, progression, or outcome of auto-
immune/infl  ammatory disease, cancer, hematopoietic grafts, 
and infections (  8  ). 
  Because KIRs are expressed on mature CD56  lo  CD16  +   
NK cells, factors that infl  uence NK cell homeostasis could 
potentially infl  uence KIR acquisition in vivo. An elegant se-
ries of mouse studies using gene targeting and bone marrow 
chimeras have revealed that NK cell development requires 
IL-15R      –  expressing cells to chaperone IL-15 to the surface, 
where it is bioactive and signifi  cantly more potent in induc-
ing activation and proliferation of IL-15R          –  expressing cells 
via trans-presentation (  9, 10  ). When not bound to IL-15R    , 
IL-15 appears to have a minimal eff  ect on NK cell homeosta-
sis in vivo (  11, 12  ). In humans, mutations in IL-15R     have 
not been reported; however, NK cells are dramatically re-
duced in patients carrying mutations in the common      chain 
(    c) cytokine receptor (used in IL-15, -7, -4, -9, -2, and -21 
signal transduction), Jak3, or the shared IL-2/-15R   , whereas 
they are present in IL-7R      –  defi  cient patients, suggesting that 
IL-15 may regulate human NK cell development (  13, 14  ). 
  In vivo studies of NK cells have been largely restricted to 
mice, and although this line of experimentation is valuable, 
some of this knowledge is not transferable to human NK cell 
biology. A clear example of this is NK cell development, 
where the kinetics, frequency, and phenotype are clearly dif-
ferent between species (  1  ). An intermediate between mouse 
and human in vivo studies exists in the form of human im-
mune system (HIS) mice. A recently developed HIS mouse 
model is the engraftment of newborn BALB/c Rag2      /         c      /      
mice with human hematopoietic stem cells (HSCs) from fetal 
liver or cord blood (  15, 16  ). BALB/c Rag2      /         c      /      HIS 
mice represent a practical HIS model with high human chime-
rism, most lymphocyte lineages generated, and adaptive 
immune responses occasionally evoked (  15, 16  ). 
  In this study, using HIS BALB/c Rag2      /         c      /      mice en-
grafted with fetal liver HSCs, we study the in vivo role of 
IL-15 trans-presentation in human NK cell homeostasis. JEM VOL. 206, January 19, 2009  27
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    Figure 1.         NK cells develop and populate various lymphoid tissues in HIS mice.   (A) 8 wk after CD34  + CD38       HSC engraftment, various organs from 
HIS mice were analyzed for human NK cell reconstitution by fl  ow cytometry (human CD45; hCD45). FACS plots are representative. Values represent mean 
percentage   ±   SEM of eight mice. (B) The cellularity of the indicated organs was enumerated and the number of hCD45  +   cells was determined based of 
fl  ow cytometry data. Numbers of cells in bone marrow (BM) are per femur and in blood are per milliliter. Values represent mean   ±   SEM of eight mice. 
Human NK cells were analyzed in the thymus (C) and spleen or bone marrow (D) by fl  ow cytometry using antibodies against the indicated human anti-
gens. Events shown were pre-gated on hCD45  +  . FACS plots are representative of eight HIS mice, with a total of three different donor HSCs represented. 
(E) 5   ×   10  4   CD56 +   NK cells were purifi  ed from spleen and bone marrow of HIS mice and stimulated in vitro with IL-12 and -18 or 5   ×   10  5   K562 CML cells 
in the presence of IL-15 for 18 h. Cells were stained with anti-CD107a or fi  xed, permeabilized, and stained with anti  –  IFN-     or anti  –  granzyme B and ana-
lyzed by fl  ow cytometry. (F) 2   ×   10  5   CD56 +   NK cells purifi  ed from human peripheral blood were labeled with CFSE and cultured in hIL-15 (gray line) or 
mIL-15 (black line) for 120 h. CFSE histograms of CD56  lo CD16 +   (black line) and CD56  hi CD16       (gray line) cultured in hIL-15 are also shown. (G) 10  4   CD56 +  
NK cells purifi  ed from human peripheral blood were labeled with CFSE and cultured with the indicated combinations of human (h) and mouse (m) IL-15 
(15) and IL-15R   -Fc  (15R   ) for 72 h. Cells were analyzed by fl  ow cytometry. Numbers indicate live cells (PI       ) per well. N.D., not determined because there 
were no live cells. Histograms are representative of two individual experiments using different donor blood. (H) 8 wk after CD34  + CD38       HSC engraftment, 
FOXN1  +/      and FOXN1     /     (Nude) HIS mice were analyzed for human T and NK cell reconstitution by fl  ow cytometry. FACS plots are gated on hCD45  +   cells 
in spleen (top) and BM (bottom) and are representative of three mice of each genotype.     28 IL-15 TRANS-PRESENTATION DRIVES HUMAN NK CELL DIFFERENTIATION   | Huntington et al. 
    Figure 2.         Trans-presentation of hIL-15 promotes human NK cell homeostasis in vivo.   (A) HIS mice were injected i.p. (every 5 d for 15 d) with hIL-15, 
IL-15+IL-15R    -Fc, or PBS commencing 6 wk after reconstitution. 3 d after the last injection, bone marrow was analyzed for human NK cell reconstitution 
by fl  ow cytometry using antibodies against the indicated human antigens. (B) HIS mice treated as in A were injected i.p. with 1 mg BrdU daily on the last 
2 d before being killed. hCD45  + NKp46 +   cells from bone marrow were analyzed for intracellular proteins and incorporation of BrdU by fl  ow cytometry. 
FACS plots are representative of two individual experiments using mice engrafted with and two different CD34  +   HSC sources. (C) HIS mice were injected 
i.p. (once per week for 4 wk) with hIL-15+IL-15R    -Fc, RLI, or PBS commencing 6 wk after reconstitution. 7 d after the last injection, mice were killed and 
thymus, spleen, liver, and bone marrow were analyzed for human NK cells by fl  ow cytometry. Organ cellularities were counted and hCD45  + NKp46 +   cells 
were enumerated based on positive surface expression determined by fl  ow cytometry. Data are mean   ±   SEM of fi  ve mice in each group generated from JEM VOL. 206, January 19, 2009  29
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two different CD34  +   HSC sources. P values are given when statistically signifi  cant. (D) NK cell subsets and BrdU incorporation in the bone marrow of HIS 
mice treated as in C were analyzed by fl  ow cytometry. (E) hCD45  + NKp46 +   cells from bone marrow were analyzed for intracellular proteins and incorpora-
tion of BrdU by fl  ow cytometry. For D and E, HIS mice were treated as in C; however, mice were killed 3 d after fi  nal treatment and were injected i.p. with 
1 mg BrdU daily on the last 2 d before being killed. FACS plots are representative of two individual experiments of 3  –  5 mice per treatment group en-
grafted with two different CD34  +   HSC sources. (F) CD8 T cells in the spleen of RLI-treated HIS mice were enumerated and analyzed for BrdU incorporation 
by fl  ow cytometry. FACS plots are representative of four mice and gated on hCD45  +   cells. Histograms are further gated on CD3  + CD8 +   cells.  Cellularities 
are mean   ±   SEM of four mice.     
 
Similarly, activated human, but not mouse, myeloid cells were 
able to induce human NK cell proliferation in vitro (Fig. S2). 
Last, human NK cells are observed in athymic HIS mice 
(Rag2      /         c      /     FOXN1      /     ), ruling out a major role for 
T cell  –  derived IL-2 driving NK cell development (  Fig. 1 H  ). 
  Collectively, these data indicate that the few resident 
NK cells in HIS mice are dependent on the available hIL-15. 
Indeed, the number of human NK cells in the spleen of HIS 
mice could be further reduced after treatment with neutral-
izing antibody against human, but not mouse, IL-15 (Fig. S2). 
Furthermore, hIL-15R      +   cells known to express IL-15 and 
support NK cell development, such as members of the my-
eloid lineage, are found in the bone marrow of HIS mice 
(unpublished data) (  10, 15  ). Given this last point, it is possible 
that enhancing the chimerism of hIL-15/-15R      –  expressing 
cells will improve human NK cell development in HIS mice. 
  Given the likely dependence of human NK cells on hIL-15, 
we next treated HIS mice with the same concentration of 
hIL-15 alone or hIL-15 preincubated with hIL-15R    -Fc to 
mimic IL-15 trans-presentation in vivo. Consistent with mouse 
studies (  11, 12  ), we observed a signifi  cant increase in NK cell 
frequency when hIL-15 was complexed to IL-15R    -Fc, but 
not when administered alone (  Fig. 2 A  ).   Increased NK lym-
phopoiesis by hIL-15+IL-15R    -Fc compared with IL-15 
alone was associated with increased Bcl-xL expression and 
cell proliferation, as demonstrated by BrdU uptake and Ki-67 
expression   (    Fig. 2 B  ). These data indicate that IL-15R  –  medi-
ated human NK cells responses are more readily evoked in 
vivo when IL-15 is complexed to IL-15R    -Fc. 
  We next compared two diff  erent IL-15R agonists, both 
mimicking IL-15 trans-presentation, hIL-15+IL-15R    -Fc, 
and RLI (hIL-15 covalently linked to an hIL-15R     extended 
sushi domain, but lacking any Fc fragment) (  11, 12, 20  ). Four 
injections of 2.5   μ  g hIL-15R agonists (one per week) resulted 
in a signifi  cant increase in the number of NKp46  +   cells in all 
organs (  Fig. 2 C  ). Both these agonists markedly enhanced 
NK cell in vivo uptake of BrdU; expression of Bcl-xL, Ki-67, 
and CD69; and resulted in delayed apoptosis of NK cells 
when withdrawn from cytokines (  Fig. 2, D and E  , and not 
depicted), suggesting both proliferation and survival result 
from IL-15+IL-15R     binding to NK cells in vivo. Human 
CD8 T cells were also signifi  cantly augmented in HIS mice 
and had an obvious increase in BrdU uptake after treatment 
with RLI (  Fig. 2 F  ). Interestingly, RLI that activates both the 
IL-15R    /     and IL-15R    /    /     was consistently more eff  ective 
in vivo than noncovalent association of hIL-15+hIL-15R    -Fc 
that activates IL-15R    /     alone. This observation is in agree-
ment with in vitro studies showing RLI functions more effi   -
ciently than the noncovalent associations of IL-15 + sushi 
domain or other soluble forms of IL-15R (  20, 21  ). The evi-
dent eff  ect of RLI compared with IL-15+IL-15R    -Fc also 
indicates that the Fc protein does not contribute to the aug-
mented NK lymphopoiesis and rules out any activation of 
human NK cells through CD16. 
  Although IL-15 is known to heighten NK cell cytotoxic-
ity and induce proliferation, it also protects cells from apop-
tosis (the latter possible at lower concentrations) by suppressing 
proapoptotic Bim and elevating Bcl-2 family members such 
as Bcl-xL and Mcl-1 (  18, 22, 23  ). A clear in vivo eff  ect of 
RLI and IL-15+IL-15R    -Fc was the up-regulation of Bcl-xL 
in NK cells (  Fig. 2, B and E  ). We next asked if enhanced sur-
vival could improve NK cell reconstitution in the limiting 
hIL-15 environment of HIS mice. To address this, HSCs 
were infected with a bicistronic retrovirus encoding the pro-
survival protein Bcl-xL and GFP (to detect infected cells) in 
vitro before engrafting newborn BALB/c Rag2      /         c      /      
mice. Ectopic expression of Bcl-xL in human HSCs resulted 
in a signifi  cant increase in thymocyte and splenocyte cellular-
ity 8 wk after engraftment, with Bcl-xL  –  transduced cells 
(GFP  +  ) representing a greater proportion of hCD45  +   cells 
compared with control transduced cells in all organs (  Fig. 3, 
A  –  C  ).   NKp46  +   cells were signifi  cantly increased in thymus 
and spleen of Bcl-xL HIS mice compared with control HIS 
mice; however, this appeared to be primarily a result of in-
creased cellularity in these organs as the percentage of NK 
cells largely unchanged (  Fig. 3, D and E  ). In addition, al-
though a greater proportion of NK cells were GFP  +   in Bcl-
xL  –  infected mice compared with controls, no accumulation 
of Bcl-xL  –  expressing NK cells was observed among the most 
mature subset (CD56  lo  CD16  +  ). Lastly, the number of NK 
cells in HIS mice engrafted with Bcl-xL  –  infected HSCs, in 
terms of absolute numbers and fold diff  erence compared with 
control, were substantially lower than mice treated with trans-
presented IL-15. These fi  ndings indicate that IL-15/IL-15R     
eff  ects extend beyond providing survival signals in promoting 
human NK cell development in vivo. 
  A consistent observation in all lymphoid organs after treat-
ment with trans-presented IL-15 was the skewing of NK cell 
maturation toward the more diff  erentiated  CD56  lo  CD16  +   
phenotype. In particular, we observed signifi  cant and specifi  c 
increases in the frequency of CD16  +   NK cells and the ratio of 
CD16  +  /CD16        NK cells 7 d after the fi  nal treatment (  Fig. 4, 
A and B  ).   This in vivo accumulation is consistent with a model 
where CD56  lo  CD16  +   NK cells represents the terminal stage of 30 IL-15 TRANS-PRESENTATION DRIVES HUMAN NK CELL DIFFERENTIATION   | Huntington et al. 
highest in the thymus and elevated compared with normal fre-
quencies in human blood (typically 50  –  60%). This may result 
from greater IL-15 concentrations in our model compared with 
humans; however, the frequency of KIR  +   NK cells in human 
thymus has not been reported using all existing commercial 
antibodies to KIRs. In contrast to IL-15 trans-presentation, no 
enhanced NK cell diff  erentiation and induction of KIR expres-
sion was observed in HIS mice treated with IL-15 alone or in 
those engrafted with Bcl-xL  –  expressing HSCs (  Fig. 4 C  ). Fur-
thermore, the increase in KIR  +   NK cells did not represent an 
expansion of one CD56  lo  CD16  +  KIR  +   NK clone, as CD-
56  lo  CD16  +   NK cells expressing a combination of 1  –  5 diff  erent 
KIR members were present in this population (  Fig. 4 D  ). 
  It is unlikely the accumulation of CD56  lo  CD16  +   NK cells 
results from a preferential expansion of this subset in response 
to hIL-15 trans-presentation as both CD56  lo  CD16  +   and CD-
56  hi  CD16        NK cell subsets had a similar level of incorpo-
rated BrdU during treatment (  Fig. 5 A  ).   Although one cannot 
distinguish between CD16  +   NK cells that have incorporated 
BrdU and BrdU  +   cells that have up-regulated CD16, it is 
most likely that the latter accounts for most of the BrdU  +  CD16  +   
NK cells as CD56  lo  CD16  +   NK cells are refractory to IL-15 
stimulation in vitro (  25, 26  ), especially when compared with 
CD56  hi  CD16        NK cells (  Fig. 1 E  ). To test this hypothesis, 
we sorted and transferred either highly purifi  ed CD56  hi 
CD16       KIRs        or CD56  lo  CD16  +  KIRs        NK cells from fetal 
spleen into BALB/c Rag2      /         c      /      in the presence or ab-
sence of RLI treatment. Although we were unable to recover 
the donor cells in mice receiving PBS alone, clear popula-
tions of donor cells were recovered from RLI-treated mice 7 
d after transfer (  Fig. 5 B  ). Consistent with our hypothesis, 
trans-presented IL-15 induced the diff   erentiation of CD-
56  hi  CD16        NK cells, with between 34 and 40% of recovered 
NK cells becoming CD16  +   (  Fig. 5 B  ). In addition a fraction 
of the CD16  +   NK cells also now expressed KIRs. Similarly, 
whereas CD56  lo  CD16  +   NK cells retained this phenotype in 
the presence of RLI after transfer, expression of KIRs were 
acquired by a fraction of these CD56  lo  CD16  +   NK cells that 
lacked KIR expression before transfer (  Fig. 5 B  ). The absence 
of NK cells in non-RLI treated recipients clearly shows that 
the available mouse IL-15 is inadequate to support human 
NK cell survival and highlights the importance of a source of 
hIL-15 in HIS mice in promoting NK cell diff  erentiation. 
  Binding of IL-15 to NK cells ultimately activates signaling 
pathways stemming from STAT5 phosphorylation, such as 
activation of NF-    B, induction of cyclin D, down-regulation 
of proapoptotic proteins, and up-regulation of Bcl-2 family 
members and cytolytic granules (  18, 24, 27  ). Although it is 
clear how these signaling events promote cell division, sur-
vival, and eff  ector functions, it is not known how these path-
ways regulate acquisition of KIRs. Coordination between 
granzyme/perforin induction and KIR expression would be 
one means to limit NK cell activity during diff  erentiation, and 
whereas most NK cells express other inhibitory receptors for 
MHC-I (CD94/NKG2A and LILR) throughout development, 
it appears acquisition of KIRs is a late event and likely unique 
NK cell development and suggests that trans-presented IL-15 
promotes this diff  erentiation. CD16 expression is associated 
with human NK cell diff  erentiation and increased cyto  toxicity 
by means of increased intracellular eff  ector granules and the 
ability to perform antibody-dependent cell cytotoxicity. IL-15 
itself is known to enhance NK cell cytotoxicity via up-regulat-
ing eff  ector molecules, such as IFN-    , perforin, and granzymes 
(  24  ). Strikingly, among the enhanced CD16  +   population after 
IL-15 trans-presentation treatment, the percentage of NK cells 
expressing KIRs was also signifi  cantly elevated, resulting in a 
large increase in the KIR  +   NK cell pool, an eff  ect that is also 
more prominent with RLI (  Fig. 4 A  ). The fraction of KIR  +   
NK cells after exogenous IL-15 trans-presentation was typically 
    Figure 3.         Ectopic expression of Bcl-xL mildly augments human NK 
cell reconstitution in vivo.   Human fetal liver HSCs were infected with 
retrovirus encoding hBcl-xL and GFP or GFP alone and used to generate 
HIS mice. (A) 8 wk after engraftment, thymus, spleen, and bone marrow 
cellularities were counted and CD45  +   cells were enumerated based on 
surface expression as determined by fl  ow cytometry. (B) GFP expression 
within hCD45  +   thymocytes of HIS mice 8 wk after engraftment was de-
tected by fl  ow cytometry. (C) The percentages of GFP  +   cells within the 
human graft were enumerated by fl  ow cytometry. (D) NK cells were enu-
merated based on the data in A and surface expression hCD45 and NKp46 
determined by fl  ow cytometry. (E) NK cell subsets were analyzed by fl  ow 
cytometry to detect surface expression of CD56 and CD16. FACS plots are 
pre-gated on hCD45  +   cells and are representative of three to four mice in 
each group. Data in A and D are mean   ±   SEM of 3  –  6 mice in each group. 
P values are given when statistically signifi   cant.   JEM VOL. 206, January 19, 2009  31
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observe accumulation of CD16  +  KIR  +   NK cells in HIS mice 
with HSCs ectopically expressing Bcl-xL suggests that NK cell 
survival alone is not suffi   cient to promote diff  erentiation and a 
source of hIL-15 is essential for this process. 
  Factors regulating KIR expression on developing NK cells 
in vivo are undefi  ned. Our study provides the fi  rst evidence 
that trans-presented IL-15 induces KIR expression on CD-
56  lo  CD16  +   NK cells in vivo and suggests that KIRs are ex-
pressed after CD16 and that acquisition of KIRs represents a 
further step in NK cell diff  erentiation. Interestingly, expression 
of human self  –  MHC-I on a fraction of the hematopoietic cells 
in HIS mice appears suffi   cient in generating phenotypically 
mature KIR  +   NK cells. Our fi  ndings suggest use of hIL-15R 
agonists in vivo may augment human NK cell diff  erentiation, 
and subsequently functionality, and could benefi  t patients with 
compared with other forms of MHC-I  –  mediated inhibition. 
Collectively, these data provide the fi  rst in vivo demonstra-
tion that trans-presented IL-15 is essential for NK cell survival 
and subsequent diff  erentiation and that KIR expression on 
mature NK cells is dynamically regulated by IL-15 signaling. 
  Concluding remarks 
  Mouse studies show that IL-15 functions as a membrane-
bound cytokine that can only be present at the cell surface and 
support NK cell development when bound to IL-15R     on 
the same cell (  9, 10  ). The clear eff  ect of hIL-15R     to enhance 
hIL-15 activity in vivo suggests this is also likely in man. Our 
fi  ndings using a novel HIS mouse approach demonstrates that 
hIL-15 trans-presentation is necessary to promote human NK 
cell development and diff  erentiation in vivo. The failure to 
    Figure 4.         HIL-15R agonists promote NK cells differentiation in vivo.   (A) NK cell maturation and KIR expression was analyzed in thymus, bone 
marrow, and spleen of HIS mice treated as in Fig. 2 C by fl  ow cytometry for surface expression of CD56, CD16, and KIRs (KIR-2DL2/3/1/-2DS1/2/4/-3DL1/S1). 
HIS mice were killed 7 d after the last treatment. Histograms are gated on hCD45  + CD56 lo CD16 +   cells and are representative of fi  ve mice and two dif  ferent CD34  +   
HSC sources. **, P   <   0.01; *, P   <   0.05. (B) The ratio of CD16  + /CD16       NK  cells  (hCD45 + NKp46 +  ) in HIS mice treated with RLI and PBS as in Fig. 2 C were deter-
mined. Data are mean   ±   SEM of four mice in each group. P values are given when statistically signifi  cant. (C) Expression of KIRs (KIR-2DL2/3/1/-2DS1/2/4/
-3DL1/S1) on CD56  lo CD16 +   in HIS mice treated as in Fig. 2 A or engrafted with modifi  ed HSCs as in   Fig. 3  . FACS plots were pre-gated on hCD45  +   and  are 
rep  resentative of at least three mice in each group. (D) Expression of KIR2DL1/2/3 was analyzed on KIR3DL1/DS1  +   or  KIR3DL1/DS1 —   NK cells in the bone 
marrow of HIS mice treated with RLI as in Fig. 2 C. FACS plots are gated on hCD45  + CD56 + CD3       and are representative of three mice.     32 IL-15 TRANS-PRESENTATION DRIVES HUMAN NK CELL DIFFERENTIATION   | Huntington et al. 
  In vivo treatments.     HIS mice were injected i.p. with 100   μ  l of hIL-15 
(2.5   μ  g) and hIL-15R    -Fc (7.5   μ  g) + hIL-15 (2.5   μ  g) both from R  &  D Systems, 
2.5   μ  g RLI (  20  ), or PBS alone, commencing at a minimum of 6 wk after re-
constitution. 100   μ  l of 10 mg/ml of BrdU from BrdU fl  ow kit (BD) was in-
jected i.p. daily 2 d before sacrifi  cing mice. For NK cell transfer assays, 3   ×   10  4   
CD56  hi  CD16       KIRs        or 2   ×   10  5   CD56  lo  CD16  +  KIRs        NK cells were 
sorted from human CD45  +  CD3        fetal splenocytes (15-wk gestation) and 
transferred intrheaptically into 1-wk-old sublethally irradiated BALB/c 
Rag2      /         c      /      mice. A cocktail of KIR antibodies recognizing KIR-
2DL2/3/1/-2DS1/2/4/-3DL1/S1 was used. Recipients were then treated 
i.p. with PBS or 2.5   μ  g of RLI on day 0 and 4 after transfer. IL-15 in vivo 
neutralization was performed by i.p. administration of 50   μ  g of goat anti  –
  hIL-15 or 25   μ  g of goat anti  –  mouse IL-15 (both from R  &  D Systems) every 
second day for 7 d. 
  Flow cytometry analysis for cell surface and intracellular markers.   
  Cell suspensions were labeled with mAb against the following human cell 
surface markers: CD3 (SK7), CD4 (SK3), CD34 (581), CD8 (SK1), CD19 
(HIB19), CD10 (HI10a), CD38 (HB7), NKG2D (1D11), NKp46 (9E2), 
CD16 (3G8), CD161 (DX12), CD56 (B159), HLA-DR (L243), HLA-A/
B/C (G46-2.6), CD117 (YB5.B8), IgD (IA6-2), IgM (G20-127), CD14 
(M5E2), CD122 (Mik-    3), TCR-    /     (T10B9.1A-31), CD127 (hIL-7R-
M21), CD11c (B-ly6), CD7 (M-T701), CD107a (1D4B), CD45 (2D1), 
CD69 (L78), Bcl-2 (Bcl-2/100), IFN-     (XMG1.2), BrdU (B44), and Ki67 
(B56) from BD; KIR2DL2/L3 (DX27), KIR3DL1 (DX9), CD94 (DX22), 
NKp44 (p44-8), CD27 (O323), CD62L (DREG-56), and NKp30 (P30-15) 
from BioLegend; KIR2DS4 (FES172), KIR2DL1/DS1 (EB6B), KIR2DL2/
L3/DS2 (GL183), KIR3DL1/DS1 (Z27.3.7), Bcl-xL (7B2.5), and CD159a 
(NKG2A; Z199) from Beckman Coulter; granzyme B (GB11) from Invitro-
gen; and CD11b (ICRF44), CD25 (BC96), CD116 (4H1), CD83 (HB15e), 
anti  –  mouse NK1.1, CD11b, CD11c, F480, and DX5 from eBioscience. In-
tracellular staining was performed after fi  xation and permeabilization of the 
cellular suspensions using Perm/Wash and Cytofi  x/Cytoperm reagents from 
BD according to the manufacturer  ’  s instruction. For BrdU detection, cells 
were incubated for 1 h at 37  °  C with 30   μ  g DNase from BrdU fl  ow kits 
(BD). All washings and reagent dilutions were done with PBS containing 2% 
FCS. All acquisitions were performed using LSRII, Canto 1, or Canto 2 cy-
tometers, cell sorting was performed using FACSAria, and all machines were 
interfaced to the FACSDiva software (BD). 
  Cell preparation.     Human fetal liver was obtained from elective abor-
tions, with gestational age ranging from 14 to 20 wk. Experiments using 
human fetal liver cells were approved by the Medical and Ethical Commit-
tees at the Institut Pasteur and AMC-UvA and performed in full compli-
ance with French law. Single-cell suspensions of fetal material were 
achieved by mechanical disruption using a Stomacher Biomaster laboratory 
system (Seward). Magnetic enrichment of CD34  +   cells (  >  98% pure) was 
performed by using the CD34 Progenitor Cell Isolation kit (Miltenyi Bio-
tech, Auburn, CA), after preparation of single-cell suspension and isolation 
of mononuclear cells by density gradient centrifugation over Ficoll-
Hypaque (Nycomed Pharma). Cell suspensions were prepared in RPMI 
medium with 2% FCS. Single-cell suspensions of mouse organs were pre-
pared as previously described (  17  ). 
  In vitro assays.     Human NK cells were purifi  ed from donor blood buff  y 
coat prepared by density gradient centrifugation over Ficoll-Hypaque (Ny-
comed Pharma) using anti-CD56 magnetic beads (Miltenyi Biotech). 
C57BL/6 splenic NK cells were purifi  ed by anti-DX5 magnetic beads (Milt-
enyi Biotech). Purifi  ed cells were loaded with 5   μ  M CFSE (Invitrogen) and 
cultured at 2   ×   10  5   cells/ml in RPMI with 10% FCS and 10 ng/ml rhIL-15 
(rhIL-15; R  &  D Systems) or 30 ng/ml rmIL-15 (Peprotech) for 3 or 5 d. Al-
ternatively, 10  4   CD56  +   NK cells purifi  ed from human peripheral blood were 
labeled with CFSE and cultured for 72 h in combinations of human or 
mouse IL-15 that had been preincubated with human or mouse IL-15R    -
Fc for 1 h at 4  °  C. The fi  nal concentration of IL-15 and IL-15R    -Fc were 
underrepresented populations of mature cytotoxic KIR  +   NK 
cells and improve NK cell  –   or CD8 T cell  –  based cancer 
immuno  therapy strategies. The effi   ciency of IL-15R agonists, 
particularly RLI, in augmenting human NK cell development 
in HIS mice will enable us to more readily dissect the role of 
IL-15-dependent lymphocytes (NK cell, memory CD8 T cell, 
NK T cell, and     /     T cell) responses to human pathogens and 
disease in vivo. Given obvious cross talk between innate and 
adaptive immune cells, having robust reconstitution of IL-15  –
  dependent cells in vivo improves the accuracy and application 
of HIS mice for studying human immune responses. Collec-
tively, our results defi  ne an essential role for IL-15 in human 
NK cell development in vivo and demonstrate the effi   cacy of 
IL-15  –  IL-15R     complexes in promoting human NK cell 
homeostasis, suggesting hIL-15 is likely bound and trans-pre-
sented by IL-15R      –  expressing cells in man. 
    MATERIALS AND METHODS   
  Mice.     C57BL/6 mice were purchased from Harlan. Rag2      /         c      /      mice 
were backcrossed onto the BALB/c background and BALB/c Rag2      /         c      /      
mice on a Nude background were bred and maintained in isolators with au-
toclaved food and water under a protocol approved by the AMC-UVA. 
Mice with a HIS were generated as previously described (  15, 16  ). In brief, 
newborn (3  –  5-d-old) Rag2      /         c      /      mice received sublethal (3.3 Gy) total 
body irradiation from a Cs source, and were injected intrahepatically with 
10  5   sorted CD34  +  CD38        or 5   ×   10  5   CD34  +   human fetal liver cells. All ma-
nipulations of HIS mice were performed under laminar fl  ow. Mouse experi-
ments were approved by an institutional committee at the Institut Pasteur 
and validated by the French Ministry of Agriculture. 
  Figure 5.       IL-15-dependent development of CD16  +  KIR  +   NK cells 
from CD16       KIR        precursors in vivo.   (A) NK cell subsets in the bone 
marrow of RLI-treated HIS mice from Fig. 2 D were analyzed for BrdU 
uptake using fl  ow cytometry. FACS plots are representative of two indi-
vidual experiments of three to fi  ve mice per treatment group engrafted 
with two different CD34  +   HSC sources. (B) CD56  hi CD16     KIRs       or 
CD56  lo CD16 + KIRs       NK cells were FACS sorted from fetal spleen 
(CD45  + CD3      ) and transferred intrahepatically into 1-wk-old sublethally 
irradiated Rag2     /     c    /     recipients for 7 d. Mice were treated i.p. with 2.5   μ  g 
RLI or PBS on day 0 and 4 after transfer. Sorted KIRs        NK cells lacked 
KIR-2DL2/3/1/-2DS1/2/4/-3DL1/S1 expression. Data are representative of 
four mice per NK subset transferred and two mice per treatment group.     JEM VOL. 206, January 19, 2009  33
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5 and 20 ng/ml, respectively. In vitro restimulation of HIS-derived NK cells 
was performed using CD56  +   NK cells purifi  ed by magnetic beads (Miltenyi 
Biotech) from a cell suspension of spleen and bone marrow from seven HIS 
mice pooled together. NK cells were cultured at 2.5   ×   10  5   cells/ml in RPMI 
supplemented with 10% FCS, rhIL-15 (5 ng/ml), and either rhIL-12 (5 ng/ml) + 
rhIL-18 (20 ng/ml; R   &   D Systems) or 2.5   ×   10  6   K562 cells/ml (American 
Type Culture Collection) for 18 h, with brefeldin A (Sigma-Aldrich) added 
for the last 4 h of culture. 
  Retroviral Bcl-xL expression.     Human fetal liver cells were prepared and 
modifi  ed by retroviral transduction as follows. The sorted CD34  +  CD38        
fetal liver cells were cultured overnight in IMDM (Invitrogen) supplemented 
with Yssel  ’  s medium, 5% normal human serum, 20 ng/ml human stem cell 
factor, 20 ng/ml human thrombopoietin, and 20 ng/ml human IL-7 (Pepro-
Tech). The next day, cells were incubated for 6  –  8 h with control LZRS 
IRES-GFP or LZRS Bcl-xL-IRES-GFP virus supernatant in fi  bronectin-
coated plates (30   μ  g/ml; Takara Biomedicals). The cell bulk was then inocu-
lated intrahepatically to the newborn recipients. The cDNA sequence 
encoding Bcl-xL, initially provided by the laboratory of J.G. Collard (The 
Netherlands Cancer Institute, Amsterdam, Netherlands) was inserted into 
the multiple cloning sites of LZRS vector upstream of an internal ribosomal 
entry site and enhanced GFP (  28  ). Control vectors were empty LZRS IRES. 
Retroviral supernatants were produced as previously described (  29  ) using the 
293T-based Phoenix packaging cell line (  30  ). 
  Online supplemental material.     Fig. S1 shows lymphocyte reconstitution 
in HIS mice. Fig. S2 shows in vitro NK cell cultures and in vivo IL-15 neu-
tralization. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20082013/DC1. 
  We acknowledge the Bloemenhove Clinic (Heemstede, The Netherlands) for 
providing fetal tissues. We would like to thank Allison Bordack, Dr. Jean-Jacques 
Mention, Dr. Ferenc Scheeren, Joran Volmer, and Jenny Meerding for reagents and 
technical assistance and Prof. Andreas Strasser for critiques on the manuscript. 
  This work is supported by grants from Institut Pasteur, Institut National de la 
Sant  é   et de la Recherche M  é  dicale, Ligue National Contre le Cancer, National Health 
and Medical Research Council of Australia, The Menzies Foundation, and a Grand 
Challenges in Global Health grant from the Bill and Melinda Gates Foundation. 
Authors from the Institut Pasteur and Academic Medical Center are part of the 
Human Vaccine Consortium   “  Grand Challenges in Global Health: Devise Reliable 
Testing Systems for New Vaccines:” (http://www.hv-consortium.org). 
  The authors have no confl  icting fi  nancial interest. 
Submitted:   9 September 2008 
Accepted:   24 November 2008 
  REFERENCES 
       1  .   Huntington  ,   N.D.  ,   C.A.     Vosshenrich  , and   J.P.     Di Santo  .   2007  . 
  Developmental pathways that generate natural-killer-cell diversity in 
mice and humans.       Nat. Rev. Immunol.       7  :  703    –    714  .    
       2  .   Jacobs  ,   R.  ,   M.     Stoll  ,   G.     Stratmann  ,   R.     Leo  ,   H.     Link  , and   R.E.     Schmidt  . 
  1992  .   CD16- CD56+ natural killer cells after bone marrow transplanta-
tion.       Blood      .     79  :  3239    –    3244  .   
       3  .   Gottschalk  ,   L.R.  ,   R.A.     Bray  ,   H.     Kaizer  , and   H.M.     Gebel  .   1990  .   Two 
populations of CD56 (Leu-19)+/CD16+ cells in bone marrow trans-
plant recipients.       Bone Marrow Transplant.       5  :  259    –    264  .   
       4  .   Chan  ,   A.  ,   D.L.     Hong  ,   A.     Atzberger  ,   S.     Kollnberger  ,   A.D.     Filer  ,   C.D.   
  Buckley  ,   A.     McMichael  ,   T.     Enver  , and   P.     Bowness  .   2007  .   CD56bright 
human NK cells diff  erentiate into CD56dim cells: role of contact with 
peripheral fi  broblasts.       J. Immunol.       179  :  89    –    94  .   
       5  .   Romagnani  ,   C.  ,   K.     Juelke  ,   M.     Falco  ,   B.     Morandi  ,   A.     D  ’  Agostino  , 
  R.     Costa  ,   G.     Ratto  ,   G.     Forte  ,   P.     Carrega  ,   G.     Lui  ,   et al  .   2007  . 
  CD56brightCD16- killer Ig-like receptor- NK cells display longer telo-
meres and acquire features of CD56dim NK cells upon activation.   
    J. Immunol.       178  :  4947    –    4955  .   34 IL-15 TRANS-PRESENTATION DRIVES HUMAN NK CELL DIFFERENTIATION   | Huntington et al. 
requires the translation of a pre-existing pool of granzyme B and perfo-
rin mRNAs.       Immunity      .     26  :  798    –    811  .    
        25  .   Carson  ,   W.E.  ,   J.G.     Giri  ,   M.J.     Lindemann  ,   M.L.     Linett  ,   M.     Ahdieh  ,   R.   
  Paxton  ,   D.     Anderson  ,   J.     Eisenmann  ,   K.     Grabstein  , and   M.A.     Caligiuri  . 
  1994  .   Interleukin (IL) 15 is a novel cytokine that activates human 
natural killer cells via components of the IL-2 receptor.       J. Exp. Med.     
  180  :  1395    –    1403  .    
        26  .   Cooley  ,  S.  ,  F.    Xiao  ,  M.    Pitt  ,  M.    Gleason  ,  V.    McCullar  ,  T.L.    Bergemann  , 
  K.L.     McQueen  ,   L.A.     Guethlein  ,   P.     Parham  , and   J.S.     Miller  .   2007  . 
  A subpopulation of human peripheral blood NK cells that lacks in-
hibitory receptors for self-MHC is developmentally immature.       Blood      .   
  110  :  578    –    586  .    
        27  .   Giron-Michel  ,   J.  ,   M.     Giuliani  ,   M.     Fogli  ,   D.     Brouty-Boye  ,   S.     Ferrini  , 
  F.     Baychelier  ,   P.     Eid  ,   C.     Lebousse-Kerdiles  ,   D.     Durali  ,   R.     Biassoni  , 
  et al  .   2005  .   Membrane-bound and soluble IL-15/IL-15Ralpha com-
plexes display diff  erential signaling and functions on human hematopoi-
etic progenitors.       Blood      .     106  :  2302    –    2310  .    
        28  .   Jaleco  ,   A.C.  ,   A.P.     Stegmann  ,   M.H.     Heemskerk  ,   F.     Couwenberg  ,   A.Q.   
  Bakker  ,   K.     Weijer  , and   H.     Spits  .   1999  .   Genetic modifi  cation of human 
B-cell development: B-cell development is inhibited by the dominant 
negative helix loop helix factor Id3.       Blood      .     94  :  2637    –    2646  .   
        29  .   Heemskerk  ,   M.H.  ,   B.     Blom  ,   G.     Nolan  ,   A.P.     Stegmann  ,   A.Q.     Bakker  , 
  K.     Weijer  ,   P.C.     Res  , and   H.     Spits  .   1997  .   Inhibition of T cell and pro-
motion of natural killer cell development by the dominant negative he-
lix loop helix factor Id3.       J. Exp. Med.       186  :  1597    –    1602  .    
        30  .   Kinsella  ,   T.M.  , and   G.P.     Nolan  .   1996  .   Episomal vectors rapidly and 
stably produce high-titer recombinant retrovirus.       Hum. Gene Ther.     
  7  :  1405    –    1413  .                  